NovaBay, a bio-pharmaceutical company focused on products to prevent a wide range of infections, filed terms Friday for its upcoming IPO. The company plans to offer 5 million shares at a price range of $4 to $6 per share. Dundee and Desjardins Securities are the lead managers on the deal.
